PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)

Detalles Bibliográficos
Autores principales: DeZern, A., Marconi, G., Deeren, D., Diez Campelo, M., Lübbert, M., Krishnamurthy, P., Nagy, Z., Basak, G., Jonášová, A., Morozova, E., Geissler, K., Ofran, Y., Kelley, H., Volkert, A., Baker, K., Kang-Fortner, Q., Hodgson, G., Madigan, C., Roth, D. A., Kelly, M., Fenaux, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431763/
http://dx.doi.org/10.1097/01.HS9.0000850536.85159.f8
_version_ 1784780145390780416
author DeZern, A.
Marconi, G.
Deeren, D.
Diez Campelo, M.
Lübbert, M.
Krishnamurthy, P.
Nagy, Z.
Basak, G.
Jonášová, A.
Morozova, E.
Geissler, K.
Ofran, Y.
Kelley, H.
Volkert, A.
Baker, K.
Kang-Fortner, Q.
Hodgson, G.
Madigan, C.
Roth, D. A.
Kelly, M.
Fenaux, P.
author_facet DeZern, A.
Marconi, G.
Deeren, D.
Diez Campelo, M.
Lübbert, M.
Krishnamurthy, P.
Nagy, Z.
Basak, G.
Jonášová, A.
Morozova, E.
Geissler, K.
Ofran, Y.
Kelley, H.
Volkert, A.
Baker, K.
Kang-Fortner, Q.
Hodgson, G.
Madigan, C.
Roth, D. A.
Kelly, M.
Fenaux, P.
author_sort DeZern, A.
collection PubMed
description
format Online
Article
Text
id pubmed-9431763
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94317632022-08-31 PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1) DeZern, A. Marconi, G. Deeren, D. Diez Campelo, M. Lübbert, M. Krishnamurthy, P. Nagy, Z. Basak, G. Jonášová, A. Morozova, E. Geissler, K. Ofran, Y. Kelley, H. Volkert, A. Baker, K. Kang-Fortner, Q. Hodgson, G. Madigan, C. Roth, D. A. Kelly, M. Fenaux, P. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431763/ http://dx.doi.org/10.1097/01.HS9.0000850536.85159.f8 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Publication Only
DeZern, A.
Marconi, G.
Deeren, D.
Diez Campelo, M.
Lübbert, M.
Krishnamurthy, P.
Nagy, Z.
Basak, G.
Jonášová, A.
Morozova, E.
Geissler, K.
Ofran, Y.
Kelley, H.
Volkert, A.
Baker, K.
Kang-Fortner, Q.
Hodgson, G.
Madigan, C.
Roth, D. A.
Kelly, M.
Fenaux, P.
PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
title PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
title_full PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
title_fullStr PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
title_full_unstemmed PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
title_short PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
title_sort pb1921: a randomized, double-blind, phase 3 study of tamibarotene/azacitidine versus placebo/azacitidine in newly diagnosed adult patients selected for rara-positive hr-mds (select-mds-1)
topic Publication Only
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431763/
http://dx.doi.org/10.1097/01.HS9.0000850536.85159.f8
work_keys_str_mv AT dezerna pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT marconig pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT deerend pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT diezcampelom pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT lubbertm pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT krishnamurthyp pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT nagyz pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT basakg pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT jonasovaa pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT morozovae pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT geisslerk pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT ofrany pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT kelleyh pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT volkerta pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT bakerk pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT kangfortnerq pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT hodgsong pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT madiganc pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT rothda pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT kellym pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1
AT fenauxp pb1921arandomizeddoubleblindphase3studyoftamibaroteneazacitidineversusplaceboazacitidineinnewlydiagnosedadultpatientsselectedforrarapositivehrmdsselectmds1

Ejemplares similares